JP4800969B2 - プロリニルアリールアセトアミド - Google Patents

プロリニルアリールアセトアミド Download PDF

Info

Publication number
JP4800969B2
JP4800969B2 JP2006544256A JP2006544256A JP4800969B2 JP 4800969 B2 JP4800969 B2 JP 4800969B2 JP 2006544256 A JP2006544256 A JP 2006544256A JP 2006544256 A JP2006544256 A JP 2006544256A JP 4800969 B2 JP4800969 B2 JP 4800969B2
Authority
JP
Japan
Prior art keywords
phenyl
chlorophenyl
methylamino
hydroxypyrrolidine
dicarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006544256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513988A5 (https=
JP2007513988A (ja
Inventor
ヴェルナー メデルスキー，
クリストス ツァクラキディス，
ディーター ドルシュ，
ベルトラム セザンヌ，
ヨハンネス グライツ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2007513988A publication Critical patent/JP2007513988A/ja
Publication of JP2007513988A5 publication Critical patent/JP2007513988A5/ja
Application granted granted Critical
Publication of JP4800969B2 publication Critical patent/JP4800969B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2006544256A 2003-12-16 2004-11-26 プロリニルアリールアセトアミド Expired - Fee Related JP4800969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10358814.0 2003-12-16
DE10358814A DE10358814A1 (de) 2003-12-16 2003-12-16 Prolinylarylacetamide
PCT/EP2004/013509 WO2005058817A1 (de) 2003-12-16 2004-11-26 Prolinylarylacetamide

Publications (3)

Publication Number Publication Date
JP2007513988A JP2007513988A (ja) 2007-05-31
JP2007513988A5 JP2007513988A5 (https=) 2008-01-17
JP4800969B2 true JP4800969B2 (ja) 2011-10-26

Family

ID=34683363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544256A Expired - Fee Related JP4800969B2 (ja) 2003-12-16 2004-11-26 プロリニルアリールアセトアミド

Country Status (16)

Country Link
US (1) US7732481B2 (https=)
EP (1) EP1697318B1 (https=)
JP (1) JP4800969B2 (https=)
KR (1) KR20060113729A (https=)
CN (1) CN1894210A (https=)
AR (1) AR046765A1 (https=)
AT (1) ATE406350T1 (https=)
AU (1) AU2004299197B2 (https=)
BR (1) BRPI0417630A (https=)
CA (1) CA2549589A1 (https=)
DE (2) DE10358814A1 (https=)
ES (1) ES2310772T3 (https=)
MX (1) MXPA06006740A (https=)
RU (1) RU2006125509A (https=)
WO (1) WO2005058817A1 (https=)
ZA (1) ZA200605841B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
MY146623A (en) 2006-05-16 2012-09-14 Boehringer Ingelheim Int Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2009000878A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
WO2011027888A1 (ja) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 ジアミド－フェニル誘導体、またはその薬学的に許容される塩
CN109761957B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
BRPI0408444A (pt) * 2003-04-03 2006-04-04 Merck Patent Gmbh derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
PL377633A1 (pl) * 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
KR20060113729A (ko) 2006-11-02
DE502004007959D1 (de) 2008-10-09
ZA200605841B (en) 2007-10-31
US7732481B2 (en) 2010-06-08
DE10358814A1 (de) 2005-07-21
CN1894210A (zh) 2007-01-10
AU2004299197B2 (en) 2010-08-05
EP1697318B1 (de) 2008-08-27
MXPA06006740A (es) 2006-08-18
US20070185189A1 (en) 2007-08-09
WO2005058817A1 (de) 2005-06-30
ATE406350T1 (de) 2008-09-15
JP2007513988A (ja) 2007-05-31
EP1697318A1 (de) 2006-09-06
AR046765A1 (es) 2005-12-21
RU2006125509A (ru) 2008-01-27
CA2549589A1 (en) 2005-06-30
ES2310772T3 (es) 2009-01-16
BRPI0417630A (pt) 2007-03-27
AU2004299197A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
US20080081814A1 (en) Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa
JP2008513387A (ja) カルボニル化合物を含む医薬およびこの使用
JP4732757B2 (ja) カルボキサミド
JP4990627B2 (ja) カルボキサミド誘導体
JP4800969B2 (ja) プロリニルアリールアセトアミド
US7683093B2 (en) Prolinyl derivatives for the treatment of thrombosis
JP4699985B2 (ja) カルボキサミド誘導体及びその第Ｘａ因子の阻害剤としての使用
JP4567439B2 (ja) カルボン酸アミド
US20070161623A1 (en) Urea derivatives
US20060135515A1 (en) Heterocyclic amides and their use treating thromboembolic diseases and tumors
US20070265259A1 (en) Proline Derivatives
MXPA06006593A (en) Carboxamide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071122

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110804

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140812

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees